Study on pharmacokinetics of 20 (S) -protopanaxadiol lipid cubic nanoparticles.
- Author:
Xin JIN
1
;
Zhen-Hai ZHANG
;
E SUN
;
Qi-Yuan LIU
;
Xiao-Bin JIA
Author Information
- Publication Type:Journal Article
- MeSH: Absorption; Administration, Oral; Animals; Antidepressive Agents; administration & dosage; blood; pharmacokinetics; Biological Availability; Chromatography, High Pressure Liquid; methods; Female; Lipids; administration & dosage; blood; pharmacokinetics; Male; Nanoparticles; Rats; Rats, Sprague-Dawley; Sapogenins; administration & dosage; blood; pharmacokinetics; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; methods; Time Factors
- From: China Journal of Chinese Materia Medica 2013;38(2):263-268
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo establish a high-performance liquid chromatographic/tandem mass spectrometry (HPLC-MS/MS) method for determining 20(S)-protopanaxadiol (PPD) in rat plasma, in order to analyze pharmacokinetic characteristics of PPD and PPD cubic nanoparticles.
METHODSprague-Dawley rats were administered orally with PPD and PPD cubic nanoparticles, respectively. Their blood samples were obtained from fossa orbitalis at regular time points. The mobile phase was 0.05% formic acidac etonitrile-0.05% formic acidac water (95:5). Electrospray ionization (ESI) was adopted for the quadrupole tandem mass spectrum. SCAN mode was used for the quantitative analysis, with m/z 460. 4/425.3 and m/z 622.9/318.3 (Rh2, interior label) as secondary fragment ions. The concentration of PPD in plasma was analyzed. The concentration-time curve was mapped. The data were calculated by DAS program.
RESULTThe linearity of the PPD plasma concentration determination method ranged between 10-1 407 microg x L(-1), with the limit of quantification of 2.5 microg x L(-1). Both of the inter-day and intra-day precisions (RSD) were less than 13.25%, and the accuracy (relative error) was between +/- 8.50%.
CONCLUSIONThe method was so highly specific and sensitive with less plasma that it is suitable for pharmacokinetic studies. The prepared 20(S)-protopanaxadiol lipid cubic nanoparticles can enhance its absorption in vivo. Its relative bioavailability is 166% of the raw material.
